Disclaimer
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.
This drug commentary is intended for medical and educational information only. It does not replace the current official Egyptian package leaflet, Summary of Product Characteristics (SmPC), prescribing information, or individualized medical advice. Product composition, manufacturer, marketing authorization holder, indications, strengths, availability, and approved dosing may differ between countries and may change over time. Healthcare professionals should verify the exact product and its current official prescribing information before prescribing or dispensing it.
1. Summary
Clenil Compositum Spray is a pressurized metered-dose inhaler containing two active ingredients:
- Beclometasone dipropionate — an inhaled corticosteroid (ICS) with potent local anti-inflammatory activity in the airways.
- Salbutamol — a short-acting selective β2-adrenergic receptor agonist (SABA) that produces rapid bronchodilation.
The combination therefore provides both anti-inflammatory control of airway disease and short-acting bronchodilation.
The historical formulation supplied in the Egyptian drug information cited for this product contains 50 micrograms of beclometasone dipropionate + 100 micrograms of salbutamol per metered actuation, in a 200-dose pressurized inhaler. An Italian authorized formulation with the same 50 + 100 microgram strength is also documented as a 200-dose pressurized inhalation suspension.
Importantly, Clenil Compositum should not be regarded as a modern first-line "rescue-only" treatment for an acute asthma attack. Product information specifically states that it is not intended as an emergency medicine for an acute attack. The patient should have an appropriate reliever/rescue strategy according to the current asthma management plan.
2. Brand Name
Clenil Compositum Spray
Other product presentations using the Clenil Compositum name exist internationally, including:
- Clenil Compositum 50 mcg + 100 mcg pressurized inhalation suspension.
- Clenil Compositum 250 mcg + 100 mcg pressurized inhalation suspension.
- Clenil Compositum presentations supplied with a JET inhalation device.
- Nebulized Clenil Compositum formulations in some markets.
The exact strength and device must therefore always be checked on the individual package.
The 50 + 100 microgram formulation is documented in regulatory records as a 200-dose pressurized inhaler.
3. Category
Pharmacological category:
- Inhaled corticosteroid + short-acting β2-adrenergic agonist.
- Anti-inflammatory + bronchodilator.
- Respiratory system medication.
- ATC classification for the combination: R03AK13 — adrenergics in combination with corticosteroids or other agents.
Individual components
Beclometasone dipropionate
- Inhaled glucocorticosteroid.
- Anti-inflammatory and antiallergic agent.
Salbutamol
- Selective short-acting β2-adrenergic agonist.
- Rapid-acting bronchodilator.
4. Active Ingredients
Beclometasone Dipropionate
Chemical name: Beclometasone 17,21-dipropionate.
It is a corticosteroid prodrug whose principal active metabolite is beclometasone-17-monopropionate (17-BMP). The metabolite has substantially greater glucocorticoid receptor activity than the parent compound.
Salbutamol
Also known internationally as albuterol.
It is a selective β2-adrenergic receptor agonist that relaxes bronchial smooth muscle and produces bronchodilation.
5. Pharmaceutical Form & Strength
For the Clenil Compositum Spray 50 + 100 microgram formulation:
Dosage form:
Pressurized metered-dose inhalation suspension/aerosol.
Each metered actuation delivers:
- Beclometasone dipropionate: 50 micrograms
- Salbutamol: 100 micrograms
The salbutamol amount corresponds to approximately 120 micrograms of salbutamol sulfate where the sulfate salt is used in the formulation.
Pack:
200 metered inhalations.
The older Egyptian description of a 15-g aluminum container and 200 metered inhalations is consistent with historical Clenil Compositum documentation, although packaging and propellant/device specifications may differ between markets and manufacturing generations.
6. Manufacturer & Marketing Authorization Holder
Egyptian-market information
Available Egyptian-market listings identify the product as:
Manufacturer/local production:
Arab Drug Company (ADCO), Egypt
with the product historically associated with:
Chiesi Farmaceutici / Chiesi, Italy
Egyptian drug databases currently list Clenil Compositum Spray as Arab Drug Company > Chiesi Italy.
The historical Egyptian leaflet supplied with the product states:
The Arab Drug Co., Cairo, A.R.E., under licence of Chiesi Farmaceutici S.p.A., Parma, Italy.
However, the current legal Marketing Authorization Holder (MAH) for a particular Egyptian pack should not be inferred solely from this historical statement. The MAH, manufacturing site, licensing arrangement, and packaging information should be confirmed against the current Egyptian regulatory package/registration data and the package itself.
International information
For the Italian authorized Clenil Compositum products, regulatory records identify Promedica S.r.l. as the Marketing Authorization Holder for the documented Italian presentations.
Therefore, manufacturer and MAH should not automatically be considered identical, and the information is market-specific.
7. Mechanism of Action
Beclometasone Dipropionate
Beclometasone dipropionate is an inhaled glucocorticosteroid.
After deposition in the respiratory tract, it is converted by esterases to active metabolites, particularly beclometasone-17-monopropionate (17-BMP).
The active corticosteroid:
- activates intracellular glucocorticoid receptors;
- modifies gene transcription;
- suppresses multiple inflammatory pathways;
- decreases inflammatory cell recruitment and activation;
- reduces airway mucosal edema;
- decreases inflammatory mediator production;
- reduces bronchial hyperresponsiveness;
- decreases mucus production and airway inflammation.
The result is improved control of chronic airway inflammation and a reduction in the tendency toward bronchoconstriction.
Beclometasone therefore acts primarily as a controller/anti-inflammatory component, rather than as a rapidly acting rescue drug.
Salbutamol
Salbutamol selectively stimulates β2-adrenergic receptors on bronchial smooth muscle.
Activation of β2 receptors stimulates adenylate cyclase and increases intracellular cyclic AMP, resulting in:
β2 receptor activation → increased cAMP → bronchial smooth-muscle relaxation → bronchodilation.
This produces relatively rapid relief of bronchoconstriction.
The β2 selectivity is relative rather than absolute; at higher systemic exposure, cardiovascular and metabolic β-adrenergic effects may occur.
8. Complementary Pharmacological Action
The two components act through different but complementary mechanisms:
Beclometasone dipropionate
→ suppresses airway inflammation and hyperresponsiveness.
Salbutamol
→ relaxes bronchial smooth muscle and rapidly improves airflow.
Thus, the combination addresses both major components of obstructive airway disease:
inflammation + bronchospasm.
This pharmacological rationale is consistent with the manufacturer's description of Clenil Compositum as a combination of an inhaled corticosteroid and a bronchodilator.
9. Spectrum of Activity
This medicine does not have an antimicrobial spectrum of activity.
It is not an antibiotic, antiviral, antifungal, or antiparasitic drug.
Its pharmacological activity is directed toward:
- airway inflammation;
- bronchial hyperresponsiveness;
- bronchospasm;
- reversible airflow obstruction.
Therefore, the term "spectrum of activity" is not applicable in the conventional antimicrobial sense.
10. Pharmacokinetics
Beclometasone Dipropionate
Following inhalation, drug deposition occurs in the lungs and part of the dose is swallowed.
The parent beclometasone dipropionate undergoes rapid conversion to active metabolites, particularly 17-BMP.
The parent compound has low oral bioavailability, whereas systemic exposure to 17-BMP is considerably greater.
For an inhaled MDI formulation, reported absolute bioavailability is approximately:
- 2% for unchanged beclometasone dipropionate
- approximately 62% for beclometasone-17-monopropionate
with systemic exposure arising from both pulmonary deposition and the swallowed fraction after presystemic conversion.
Peak concentrations of unchanged beclometasone dipropionate occur rapidly, while the active 17-BMP metabolite reaches its peak somewhat later.
Following intravenous administration, reported terminal half-lives are approximately:
- Beclometasone dipropionate: 0.5 hour
- 17-BMP: 2.7 hours
The drug and its metabolites are predominantly eliminated through the feces, with relatively little urinary elimination.
Clinical implication
Although inhaled beclometasone is primarily intended for local pulmonary activity, it is not completely free from systemic exposure, especially at high doses or with prolonged treatment.
Salbutamol
After inhalation, salbutamol acts predominantly in the lungs.
A fraction of the inhaled dose is deposited in the respiratory tract, while another fraction may be swallowed.
Systemically absorbed salbutamol undergoes hepatic metabolism, mainly by conjugation, and is eliminated primarily through the urine.
Systemic exposure increases with increasing dose and can result in:
- tremor;
- palpitations;
- tachycardia;
- hypokalemia;
- headache;
- metabolic effects.
11. Indications
Clenil Compositum is indicated in the treatment of:
1. Bronchial asthma
It can be used in patients for whom treatment with an inhaled corticosteroid together with a short-acting β2 agonist is considered appropriate.
2. Chronic obstructive pulmonary disease with an asthmatic component
Certain product information identifies the combination for COPD with an asthmatic component.
Important distinction
The product's historical indication should not be interpreted as meaning that every patient with COPD should receive this combination.
Modern COPD treatment is individualized according to symptoms, exacerbation risk, eosinophil count, asthma features, and other clinical factors.
12. Is Clenil Compositum a Rescue Medication?
Not as a stand-alone emergency treatment for an acute severe asthma attack.
Although salbutamol itself is a rapid bronchodilator, the combination contains beclometasone and is formulated primarily as a combined treatment rather than as a dedicated emergency rescue inhaler.
Current product information specifically states that Clenil Compositum is not indicated as an emergency medicine for acute asthma attacks.
Therefore, a patient experiencing an acute severe asthma exacerbation should follow the prescribed asthma action plan and use the appropriate reliever/emergency treatment rather than relying on Clenil Compositum alone.
This is an important correction to the older statement that the product itself provides "treatment for acute asthmatic patients."
13. Administration
Route: Oral inhalation.
The patient inhales the medication through the mouth using the metered-dose inhaler.
Because correct inhaler technique is essential for effective lung deposition, inadequate coordination between actuation and inhalation can substantially reduce treatment effectiveness.
14. Typical Historical Dosing Information
The older product information supplied for the 50 + 100 microgram formulation stated:
Adults
2 puffs per administration, 4–6 times daily, according to response.
Children
The historical leaflet stated:
1–2 puffs, 2–4 times daily, according to therapeutic response.
It also stated:
- maximum 2 puffs per administration;
- administrations should not be repeated before 4 hours;
- the effect of inhalation was described as persisting for at least approximately 4 hours.
These doses are historical product-label information and should not automatically be applied to every current formulation or patient. Different strengths, devices, ages, national labels, and current asthma treatment strategies can require different dosing.
For example, current Italian product information for the 250 + 100 microgram presentation lists a different adult regimen, illustrating why the strength must be checked before interpreting a dose.
15. Method of Preparation / Instructions for Use
For the conventional pressurized metered-dose inhaler:
Before inhalation
- Remove the protective cap.
- Inspect the mouthpiece.
- Shake the inhaler well.
- Sit or stand upright.
- Exhale fully, away from the inhaler.
Administration
- Place the mouthpiece between the lips and close the lips firmly around it.
- Begin a slow, deep inhalation through the mouth.
- At the same time, press the canister once.
- Continue inhaling slowly and deeply.
- Hold the breath for approximately 10 seconds, or as long as comfortably possible.
- Remove the inhaler and breathe out slowly.
- If another puff is prescribed, wait briefly and repeat the procedure.
The historical instructions emphasize coordinated actuation with a slow, deep inhalation and breath holding afterward.
16. Spacer / Inhalation Device
A spacer or valved holding chamber can improve delivery from a pressurized metered-dose inhaler, particularly in patients who have difficulty coordinating actuation and inhalation.
Some Clenil Compositum presentations have also been manufactured with a JET device, specifically designed to facilitate inhalation and reduce the need for precise synchronization between actuation and inspiration. Regulatory records document 50 + 100 microgram presentations supplied with a JET device.
The exact device supplied with the Egyptian product should be checked on the individual package.
17. Mouth Rinsing
After using an inhaled corticosteroid, the patient should rinse the mouth with water and spit it out.
This reduces the risk of:
- oral candidiasis;
- dysphonia;
- unpleasant taste;
- local corticosteroid deposition.
Good inhaler technique and the use of an appropriate spacer, when indicated, can further reduce local adverse effects.
18. Cleaning
The mouthpiece should be kept clean.
For a pressurized inhaler, cleaning instructions should follow the current product leaflet because the appropriate procedure depends on the device and formulation.
The historical leaflet instructed removal of the canister and cleaning/rinsing the mouthpiece with warm water before drying and replacing the canister.
Do not immerse or clean the device in a manner inconsistent with the current manufacturer's instructions.
19. Contraindications
Absolute/major contraindication
Hypersensitivity to beclometasone dipropionate, salbutamol, or any component of the formulation.
Historical product information also listed active or quiescent local viral and tuberculosis infections as contraindications for the beclometasone component. However, this should be interpreted in the context of the specific current national product label, because contraindication wording varies between formulations and regulatory jurisdictions.
Acute severe asthma attack
Clenil Compositum is not an appropriate sole emergency treatment for an acute severe asthma attack.
20. Warnings & Precautions
Cardiovascular disease
Use salbutamol-containing products cautiously in patients with:
- ischemic heart disease;
- significant arrhythmias;
- heart failure;
- uncontrolled hypertension.
Systemic β2-agonist effects may produce tachycardia, palpitations or other cardiovascular effects.
Hyperthyroidism
Salbutamol should be used cautiously in patients with hyperthyroidism because sympathomimetic effects may be enhanced.
Diabetes mellitus
β2 agonists may produce metabolic effects, including transient changes in blood glucose, particularly at higher systemic exposure.
Hypokalemia
β2 agonists can cause intracellular potassium shift and potentially produce hypokalemia, especially at high doses or in patients receiving other potassium-lowering treatments.
This becomes clinically more important in severe acute asthma or when large amounts of β2 agonists are administered.
Glaucoma
Patients with glaucoma should be treated cautiously, particularly if inhaler deposition around the eyes occurs.
Cardiovascular susceptibility
The old product information specifically advised caution in patients with coronary disease, cardiac failure, hyperthyroidism, severe hypertension, and those previously receiving high doses of other sympathomimetics.
Oral candidiasis
Inhaled beclometasone may cause oral or oropharyngeal candidiasis.
Rinsing the mouth after inhalation reduces this risk.
Dysphonia
Hoarseness and voice changes may occur because of local corticosteroid deposition.
Paradoxical bronchospasm
Rarely, inhaled medications may produce paradoxical bronchospasm immediately after administration.
If significant paradoxical bronchospasm occurs, the preparation should be discontinued and an appropriate alternative treatment instituted.
Adrenal suppression
Although inhaled corticosteroids have lower systemic exposure than oral corticosteroids, prolonged treatment with high doses can produce systemic corticosteroid effects, including:
- adrenal suppression;
- Cushingoid features;
- growth retardation in children;
- reduced bone mineral density;
- cataracts;
- glaucoma.
The risk increases with higher doses and prolonged exposure.
Systemic corticosteroid withdrawal
Patients transferred from systemic corticosteroids to inhaled corticosteroids may remain at risk of adrenal insufficiency, particularly during periods of major physiological stress.
The historical product information specifically emphasized continuing systemic corticosteroid therapy initially during certain transitions and monitoring adrenal function.
Respiratory infections
Inhaled corticosteroids may increase susceptibility to local fungal infection and can potentially influence respiratory infections.
Active untreated tuberculosis and certain untreated infections require particular caution and assessment before corticosteroid therapy.
Pneumonia in COPD
Inhaled corticosteroids may increase the risk of pneumonia in some patients with COPD. The benefit-risk balance should therefore be assessed individually.
Growth in children
Long-term inhaled corticosteroid therapy may slightly reduce growth velocity in some children.
The goal should be to use the lowest effective corticosteroid dose that maintains disease control.
21. Drug Interactions
Non-selective β-blockers
Propranolol and other non-selective β-blockers can antagonize the bronchodilator effect of salbutamol and may precipitate bronchospasm.
The historical product information specifically warned against concomitant administration with β-blockers such as propranolol.
Cardioselective β1-blockers may sometimes be used when clinically necessary, but only after individualized assessment.
Other sympathomimetics
Concomitant use with other sympathomimetic agents may increase cardiovascular adverse effects such as:
- tachycardia;
- palpitations;
- tremor;
- hypertension.
Diuretics
Non-potassium-sparing diuretics may potentiate β2-agonist-associated hypokalemia.
Digoxin
β2-agonist-induced hypokalemia may theoretically increase the risk of digoxin-associated arrhythmias.
Monoamine oxidase inhibitors and tricyclic antidepressants
These agents may enhance the cardiovascular effects of sympathomimetics. Caution is therefore appropriate, particularly in patients with cardiovascular disease.
Corticosteroid interactions
Other systemic or inhaled corticosteroids can increase cumulative corticosteroid exposure.
Strong CYP3A4 inhibitors
Beclometasone dipropionate is generally considered to have a relatively favorable interaction profile among inhaled corticosteroids, but clinically important increases in corticosteroid exposure can occur with potent CYP3A4 inhibition in some circumstances.
Examples of potent inhibitors include:
- ritonavir;
- cobicistat-containing regimens;
- certain azole antifungals such as itraconazole and voriconazole.
Evidence indicates that beclometasone may be less problematic than some other inhaled corticosteroids in this context, but caution and clinical monitoring remain appropriate when high systemic exposure is possible.
22. Side Effects
Common or relatively common effects
From salbutamol
- Fine tremor.
- Nervousness.
- Headache.
- Palpitations.
- Tachycardia.
- Muscle cramps.
From beclometasone
- Hoarseness/dysphonia.
- Throat irritation.
- Oral candidiasis.
- Unpleasant taste.
The historical Clenil Compositum leaflet particularly mentioned hoarseness and oral/throat fungal infection, as well as transient increases in heart rate and mild muscular tremor at higher doses.
Less common or clinically important effects
- Hypokalemia.
- Hyperglycemia.
- Cardiac arrhythmias.
- Paradoxical bronchospasm.
- Hypersensitivity reactions.
- Cataracts.
- Glaucoma.
- Adrenal suppression.
- Cushingoid features.
- Reduced bone mineral density.
- Growth retardation with prolonged corticosteroid exposure in children.
23. Serious Adverse Reactions Requiring Medical Attention
Urgent medical assessment is appropriate for:
- severe or rapidly worsening shortness of breath;
- paradoxical bronchospasm immediately after inhalation;
- severe palpitations or significant arrhythmia;
- angioedema or anaphylaxis;
- severe weakness associated with possible hypokalemia;
- symptoms suggestive of adrenal insufficiency;
- severe visual symptoms potentially associated with glaucoma or cataract.
24. Overdose
Salbutamol overdose
Excessive doses can produce:
- marked tremor;
- tachycardia;
- palpitations;
- hypokalemia;
- hyperglycemia;
- metabolic changes;
- potentially significant cardiac effects.
Beclometasone overdose
A single excessive inhaled dose is generally less likely to cause serious acute toxicity than prolonged high-dose exposure.
Repeated excessive dosing can produce:
- adrenal suppression;
- Cushingoid features;
- systemic corticosteroid effects.
The appropriate response depends on the amount taken and clinical status.
25. Use in Special Populations
Pregnancy
The older product information advised that the combination should be used during pregnancy only when clearly necessary and under medical supervision.
Because uncontrolled asthma itself can adversely affect pregnancy, treatment should not be stopped simply because pregnancy occurs.
The current product-specific label should be consulted to determine the exact pregnancy wording for the formulation being prescribed.
Breastfeeding
Both salbutamol and inhaled corticosteroids generally produce relatively low systemic exposure when administered appropriately by inhalation.
However, the exact recommendation should be based on the current product information and clinical assessment.
The older Italian product information listed pregnancy and breastfeeding as contraindications, but this is an example of why historical national labeling should not automatically be generalized to current international or Egyptian practice.
Children
Pediatric use depends on:
- age;
- formulation;
- strength;
- inhaler device;
- disease severity;
- current prescribing guidance.
The historical Egyptian information allowed use below 12 years, but other current formulations specify different minimum ages. For example, the current Chiesi HFA formulation documented in Brazil is authorized for adults and children above 6 years.
Therefore, the age restriction on the actual Egyptian pack must be checked rather than extrapolated from another country's formulation.
Long-term inhaled corticosteroid treatment should use the lowest effective dose and growth should be monitored when clinically appropriate.
Elderly patients
Elderly patients can generally receive inhaled beclometasone/salbutamol when clinically indicated, but greater caution may be appropriate because cardiovascular disease, arrhythmias, hypertension, glaucoma, diabetes, and polypharmacy are more common.
Renal impairment
Beclometasone dipropionate is extensively metabolized, and urinary elimination is not the major elimination route. Available pharmacokinetic information does not suggest a major need for routine dose adjustment solely because of renal impairment, although clinical context remains important.
Hepatic impairment
Beclometasone undergoes extensive metabolism, but available product information indicates that major pharmacokinetic alteration is not necessarily expected with hepatic impairment. Clinical judgment remains necessary, particularly in severe hepatic disease.
26. Storage Conditions
Storage conditions are formulation- and market-specific.
For a pressurized inhaler:
- Keep in the original packaging.
- Protect from excessive heat.
- Do not expose the pressurized canister to high temperatures.
- Do not puncture or incinerate the canister.
- Keep out of reach of children.
- Observe the expiry date printed on the package.
The current Egyptian package leaflet should be followed for the exact temperature/storage requirements, because different Clenil formulations and manufacturing generations may have different instructions.
27. Important Difference Between Clenil Compositum and Clenil Forte
These products should not be considered interchangeable on a puff-for-puff basis.
Clenil Compositum Spray
Contains:
Beclometasone dipropionate + salbutamol
The historically documented Egyptian strength is:
50 mcg beclometasone + 100 mcg salbutamol per actuation.
Clenil Forte Spray 250 mcg/dose
Contains:
Beclometasone dipropionate alone
Strength:
250 micrograms per actuation.
Egyptian-market databases currently list Clenil Forte Spray 250 mcg/dose as beclometasone dipropionate manufactured/listed by Arab Drug Company in association with Chiesi Italy.
Consequently:
Clenil Compositum ≠ Clenil Forte
and a dose of one cannot be substituted for the other simply by matching the number of puffs.
28. Other Clenil Forte Presentations
International and regulatory records demonstrate that Clenil Forte has existed in several strengths and formulations.
For example, regulatory records document Clenil Forte Spray 250 micrograms/dose, while Egyptian drug databases also list a Clenil Forte 500 micrograms/dose presentation.
Therefore, the exact strength printed on the inhaler must always be checked before calculating the daily corticosteroid dose.
29. Current Egyptian-Market Product Information
Based on currently available Egyptian-market listings retrieved in August 2026:
Clenil Compositum Spray
- Active ingredients: Beclometasone dipropionate + salbutamol
- Strength: 50 + 100 mcg/dose in the documented Egyptian listing
- Dosage form: Pressurized metered-dose inhalation suspension
- Company listed: Arab Drug Company > Chiesi Italy.
Clenil Forte Spray 250 mcg/dose
- Active ingredient: Beclometasone dipropionate
- Strength: 250 mcg/dose
- Company listed: Arab Drug Company > Chiesi Italy.
These current Egyptian-market listings are useful for identifying products available in Egypt, but official regulatory confirmation should take precedence over commercial drug databases when determining the current legal MAH, registration status, manufacturing site, or exact leaflet wording.
30. Clinical Interpretation of the Older Commentary
Several statements in the historical leaflet supplied with this article remain pharmacologically reasonable, including:
- the presence of beclometasone dipropionate and salbutamol;
- 50 mcg + 100 mcg per actuation for the historical formulation;
- 200 metered inhalations;
- complementary anti-inflammatory and bronchodilator actions;
- occurrence of hoarseness and oral candidiasis;
- possible tremor and increased heart rate;
- the importance of correct inhaler technique.
However, some statements require modern qualification:
"Treatment for acute asthmatic patients"
This wording should not be interpreted as recommending Clenil Compositum as the sole emergency treatment of an acute asthma attack. Current product information explicitly states that it is not an emergency medication for acute attacks.
"No general effects"
This is too absolute.
Inhaled beclometasone has lower systemic exposure than systemic corticosteroids, but systemic corticosteroid effects can occur, especially at high doses and with prolonged treatment.
"Without inhibiting adrenal function"
This should also not be regarded as universally true.
High-dose or prolonged inhaled corticosteroid therapy can cause adrenal suppression.
"No serious side effects at recommended doses"
This is overly broad for modern pharmacovigilance language.
Most patients tolerate therapeutic inhaled doses well, but clinically important cardiovascular, metabolic, local corticosteroid, and systemic corticosteroid adverse effects can occur in susceptible patients.
31. Practical Clinical Points
- Correct inhaler technique is essential.
- Rinse the mouth after use to reduce oral candidiasis.
- Do not confuse Clenil Compositum with Clenil Forte.
- Do not assume that the number of puffs can be transferred from one strength to another.
- Do not rely on Clenil Compositum as the sole emergency treatment of a severe acute asthma attack.
- Monitor patients receiving prolonged/high-dose inhaled corticosteroid therapy for systemic corticosteroid effects when clinically indicated.
- Exercise caution in patients with cardiovascular disease or significant arrhythmias because of salbutamol.
- Avoid non-selective β-blockers such as propranolol unless there is a compelling specialist-directed reason and appropriate monitoring.
- Consider interactions with potent CYP3A4 inhibitors when clinically relevant.
- Always verify the exact strength, device, formulation, age indication, and current local leaflet.
32. Frequently Asked Questions (FAQ)
Is Clenil Compositum a steroid?
Yes.
It contains beclometasone dipropionate, an inhaled corticosteroid, together with salbutamol, a short-acting bronchodilator.
Does Clenil Compositum contain salbutamol?
Yes.
The documented 50 + 100 microgram formulation contains 100 micrograms of salbutamol per actuation.
Does Clenil Compositum contain beclometasone?
Yes.
The documented formulation contains 50 micrograms of beclometasone dipropionate per actuation.
Is Clenil Compositum the same as Clenil Forte?
No.
Clenil Compositum contains beclometasone + salbutamol, whereas Clenil Forte is a beclometasone-only inhaler.
Can Clenil Compositum be used during an asthma attack?
It should not be relied upon as the sole emergency treatment for an acute asthma attack. Product information specifically states that it is not intended as an emergency medicine for acute attacks.
Can Clenil Compositum cause oral thrush?
Yes.
Because it contains an inhaled corticosteroid, oral/oropharyngeal candidiasis can occur.
Rinsing and spitting after inhalation reduces the risk.
Can it cause hoarseness?
Yes.
Dysphonia/hoarseness is a recognized local adverse effect of inhaled corticosteroids.
Can it cause tremor or palpitations?
Yes.
These are primarily related to the salbutamol component and are more likely with higher systemic exposure.
Can Clenil Compositum affect potassium?
Yes.
β2 agonists such as salbutamol can lower serum potassium, particularly at high doses.
Can it be used with propranolol?
Generally, this combination should be avoided or used only under appropriate specialist supervision because non-selective β-blockers can antagonize salbutamol and may provoke bronchospasm.
Is it safe in pregnancy?
Treatment decisions should be individualized.
Uncontrolled asthma itself can be harmful during pregnancy, so inhaled therapy should not be discontinued without medical advice. The current local product information should be consulted for the exact pregnancy recommendation for the formulation being used.
Can it be used in children?
Potentially, but the approved age varies by formulation and market.
The current formulation and Egyptian package leaflet should be checked rather than assuming that all Clenil Compositum products have the same pediatric indication.
Does inhaled beclometasone have systemic effects?
Usually considerably fewer than systemic corticosteroids, but systemic exposure does occur.
High-dose or prolonged therapy can cause adrenal suppression, effects on growth, bone mineral density changes, cataracts, glaucoma, and other corticosteroid-related effects.
Does it need to be stopped suddenly?
Long-term inhaled corticosteroid therapy should not be stopped or substantially changed without medical advice, particularly in patients with significant asthma or those transitioning from systemic corticosteroids.
Can Clenil Compositum be nebulized?
The spray/pressurized metered-dose formulation should not simply be placed into a nebulizer.
Separate Clenil Compositum nebulized formulations exist in some markets, but these are different pharmaceutical presentations with different concentrations and instructions.
33. References
-
Chiesi Pharmaceuticals — Clenil Compositum product information. Chiesi confirms the active ingredients as beclometasone dipropionate and salbutamol and directs healthcare professionals to the relevant current national regulatory documentation.
-
Chiesi — Clenil Compositum HFA professional information. Provides formulation, strength, route, age information, composition and clinical information for the HFA 50 + 100 microgram formulation.
-
European Medicines Agency — PSUSA information for beclometasone/salbutamol. Documents nationally authorized beclometasone/salbutamol products and their strengths and marketing authorization information.
-
Italian regulatory documentation / AIFA-derived product information for Clenil Compositum. Provides formulation, indications, dosing, contraindications and administration information.
-
Gazzetta Ufficiale della Repubblica Italiana. Regulatory records document the 50 + 100 microgram and 250 + 100 microgram Clenil Compositum pressurized inhalation presentations and 200-dose packages.
-
Egyptian drug-market databases. Used only to cross-check currently listed Egyptian-market products and company information; official Egyptian regulatory documentation should take precedence.
-
Electronic Medicines Compendium (emc). Pharmacokinetic and pharmacodynamic information for inhaled beclometasone formulations, including conversion to 17-BMP, bioavailability and elimination.
-
Saudi Drug Information System. Pharmacokinetic information for inhaled beclometasone dipropionate, including systemic bioavailability and active metabolite formation.
-
Peer-reviewed pharmacokinetic literature. Data concerning lung and systemic bioavailability of inhaled beclometasone dipropionate formulations, including Clenil.
-
Literature on inhaled corticosteroid drug interactions. Evidence concerning CYP3A4 inhibitors and inhaled corticosteroids, including beclometasone.
34. Final Clinical Summary
Clenil Compositum Spray is a combination inhaled medication containing beclometasone dipropionate + salbutamol.
The documented Egyptian-market formulation contains 50 micrograms of beclometasone dipropionate and 100 micrograms of salbutamol per actuation, supplied as a 200-dose pressurized inhaler.
Its pharmacological rationale is straightforward:
Beclometasone → controls airway inflammation
Salbutamol → produces bronchodilation
The combination can therefore be useful in appropriately selected patients with obstructive airway disease, particularly asthma, and in certain patients with COPD with an asthmatic component.
Nevertheless, it should not be confused with a corticosteroid-only Clenil Forte inhaler, and the combination should not be used as the sole emergency treatment for an acute severe asthma attack.
The older information supplied for this product contains several valid historical details, but some statements are too absolute by modern standards — particularly statements suggesting an absence of systemic corticosteroid effects and the implication that the combination itself should be used to treat acute asthma attacks.
For prescribing or dispensing in Egypt, the exact current package, strength, device, registration information, and current Egyptian official leaflet should always take precedence over historical leaflets or third-party databases.